Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

(2020) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN

(2020) Peter M Voorhees et al.   BLOOD

Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).

(2020) Saad Zafar Usmani et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).

(2020) Eric Leon Tam et al.   JOURNAL OF CLINICAL ONCOLOGY

Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial.

(2020) Katja Weisel et al.   JOURNAL OF CLINICAL ONCOLOGY

Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma

(2020) Fazal Shirazi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

(2020) Michele Cavo et al.   Lancet Haematology

Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities

(2020) Nadine Abdallah et al.   Blood Advances

Del17p without TP53 mutation confers poor prognosis in intensively treated newly diagnosed multiple myeloma patients.

(2020) Jill Corre et al.   BLOOD

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

(2020) Shaji K Kumar et al.   LANCET ONCOLOGY

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

(2020) David S. Hong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-based therapies in the management of multiple myeloma

(2020) Saurabh Zanwar et al.   Blood Cancer Journal

Multiple myeloma current treatment algorithms

(2020) S. Vincent Rajkumar et al.   Blood Cancer Journal

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma

(2019) Edward A. Stadtmauer et al.   JOURNAL OF CLINICAL ONCOLOGY

Natural history of multiple myeloma with de novo del(17p)

(2019) Arjun Lakshman et al.   Blood Cancer Journal

Mechanisms of resistance to CAR T cell therapy

(2019) Nirali N. Shah et al.   Nature Reviews Clinical Oncology

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

(2019) Philippe Moreau et al.   LANCET

MYC dysregulation in the progression of multiple myeloma

(2019) Kristine Misund et al.   LEUKEMIA

Treatment Options for Triple-class Refractory Multiple Myeloma

(2019) Joseph Mikhael   Clinical Lymphoma Myeloma & Leukemia

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

(2019) Timothy M. Schmidt et al.   Blood Cancer Journal

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

(2018) Brian A. Walker et al.   LEUKEMIA

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

(2018) Aurore Perrot et al.   BLOOD

Targeting Bcl-2 for the treatment of multiple myeloma

(2018) Cyrille Touzeau et al.   LEUKEMIA

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

(2017) Sharmilan Thanendrarajan et al.   HAEMATOLOGICA

Genomics of Multiple Myeloma

(2017) Sebastien Robiou du Pont et al.   JOURNAL OF CLINICAL ONCOLOGY

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

(2017) F Maura et al.   LEUKEMIA

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients

(2017) V Shah et al.   LEUKEMIA

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

(2017) J Flores-Montero et al.   LEUKEMIA

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

(2017) Sharmilan Thanendrarajan et al.   HAEMATOLOGICA

Multiple myeloma

(2017) Shaji K. Kumar et al.   Nature Reviews Disease Primers

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

(2017) Nikhil C. Munshi et al.   JAMA Oncology

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

(2016) K. M. Kortum et al.   BLOOD

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

(2016) P. Sonneveld et al.   BLOOD

Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation

(2016) Ulrich J.M. Mey et al.   HEMATOLOGICAL ONCOLOGY

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

(2016) Y Jethava et al.   Blood Cancer Journal

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

(2015) B. Holkova et al.   CLINICAL CANCER RESEARCH

The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma

(2015) G. An et al.   CLINICAL CANCER RESEARCH

Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

(2015) Christof Scheid et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

(2015) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

(2015) Brian A. Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene signature combinations improve prognostic stratification of multiple myeloma patients

(2015) W J Chng et al.   LEUKEMIA

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

(2015) Brian A. Walker et al.   Nature Communications

Interpretation of cytogenetic results in multiple myeloma for clinical practice

(2015) A M Rajan et al.   Blood Cancer Journal

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients

(2014) B A Walker et al.   Blood Cancer Journal

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

(2013) G. Mulligan et al.   BLOOD

Molecular pathogenesis of multiple myeloma: basic and clinical updates

(2013) Marta Chesi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma

(2013) Prashant Kapoor et al.   JOURNAL OF CLINICAL ONCOLOGY

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

(2013) C Touzeau et al.   LEUKEMIA

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

(2013) A K Nooka et al.   LEUKEMIA

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

(2013) B Hebraud et al.   LEUKEMIA

Association of response endpoints with survival outcomes in multiple myeloma

(2013) S Lonial et al.   LEUKEMIA

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

(2013) Joseph R. Mikhael et al.   MAYO CLINIC PROCEEDINGS

Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

(2012) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

ABT-737 is highly effective against molecular subgroups of multiple myeloma

(2011) L. Bodet et al.   BLOOD

The Histone Methyltransferase and Putative Oncoprotein MMSET Is Overexpressed in a Large Variety of Human Tumors

(2011) H. R. Hudlebusch et al.   CLINICAL CANCER RESEARCH

Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival

(2011) K. D. Boyd et al.   CLINICAL CANCER RESEARCH

Molecular Heterogeneity of Multiple Myeloma: Pathogenesis, Prognosis, and Therapeutic Implications

(2011) Avet-Loiseau Hervé et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

(2010) C. M. Annunziata et al.   BLOOD

MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity

(2010) Manujendra N. Saha et al.   CANCER BIOLOGY & THERAPY

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

(2010) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

(2009) O. Landgren et al.   BLOOD

Prognostic Significance of Copy-Number Alterations in Multiple Myeloma

(2009) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2

(2008) Mauricio Pineda-Roman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors

(2008) Ana Gabrea et al.   GENES CHROMOSOMES & CANCER

Clinical and biological significance of RAS mutations in multiple myeloma

(2008) W J Chng et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE